The goal of this clinical trial is to investigate the effect of propolis administration on dysmenorrhea in endometriosis patient. the main questions it aims to answer are: * Does the propolis administration reduce symptoms of dysmenorrhea in endometriosis? * Does the propolis administration reduce the amount of oxidative stress biomarkers in endometriosis? * Does the propolis administration reduce the amount of Inflammatory biomarkers in endometriosis? Participants will be given an intervention in the form of propolis at a dose of 1 drop per 10 kilogram of body weight per administration, twice a day. there will be a control group that will be given an intervention in the form of a placebo containing 70% caramel alcohol dye solution.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Enrollment
24
intervention will use propolis extract (liquid-based) with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given to intervention group
intervention will use placebo with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given control group
Cipto Mangunkusumo Hospital
Jakarta, Jakarta Pusat, Indonesia
RECRUITINGMalondialdehyde (MDA)
blood biochemical test for oxidative stress biomarker from lipid peroxidation product, using ng/mL numeric scale
Time frame: week 0
Malondialdehyde (MDA)
blood biochemical test for oxidative stress biomarker from lipid peroxidation product, using ng/mL numeric scale
Time frame: week 4
Malondialdehyde (MDA)
blood biochemical test for oxidative stress biomarker from lipid peroxidation product, using ng/mL numeric scale
Time frame: week 12
Superoxide dismutase (SOD)
blood biochemical test for oxidative stress biomarker from lipid peroxidation product, using nmol/mLnumeric scale
Time frame: week 0
Superoxide dismutase (SOD)
blood biochemical test for oxidative stress biomarker from lipid peroxidation product, using nmol/mLnumeric scale
Time frame: week 4
Superoxide dismutase (SOD)
blood biochemical test for oxidative stress biomarker from lipid peroxidation product, using nmol/mLnumeric scale
Time frame: week 12
interleukin 6
will test the outcome with ELISA test from blood sample for inflammatory biomarker, using ng/mL numeric scale
Time frame: week 0
interleukin 6
will test the outcome with ELISA test from blood sample for inflammatory biomarker, using ng/mL numeric scale
Time frame: week 4
interleukin 6
will test the outcome with ELISA test from blood sample for inflammatory biomarker, using ng/mL numeric scale
Time frame: week 12
tumor necrosis factor alpha (TNF alfa)
will test the outcome with ELISA test for inflammatory biomarker, using ng/mL numeric scale
Time frame: week 0
tumor necrosis factor alpha (TNF alfa)
will test the outcome with ELISA test for inflammatory biomarker, using ng/mL numeric scale
Time frame: week 4
tumor necrosis factor alpha (TNF alfa)
will test the outcome with ELISA test for inflammatory biomarker, using ng/mL numeric scale
Time frame: week 12
pain scale
to measure the outcome, the investigators use Visual Analogue Scale for measure the pain from the subject, from 0 to 10. The scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). the subject will be asked to rate their current level of pain by placing a mark on the line.
Time frame: week 0
pain scale
to measure the outcome, the investigators use Visual Analogue Scale for measure the pain from the subject, from 0 to 10. The scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). the subject will be asked to rate their current level of pain by placing a mark on the line.
Time frame: week 4
pain scale
to measure the outcome, the investigators use Visual Analogue Scale for measure the pain from the subject, from 0 to 10. The scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). the subject will be asked to rate their current level of pain by placing a mark on the line.
Time frame: week 12
Glutathione
measure the outcome with blood biochemical test using spectrofotometri in µg/mL numeric scale
Time frame: week 0
Glutathione
measure the outcome with blood biochemical test using spectrofotometri in µg/mL numeric scale
Time frame: week 4
Glutathione
measure the outcome with blood biochemical test using spectrofotometri in µg/mL numeric scale
Time frame: week 12
8-hydroxy-2-deoxyiguanosine (8-OHdG)
measure the outcome with ELISA from blood sample in ng/mL numeric scale
Time frame: week 0
8-hydroxy-2-deoxyiguanosine (8-OHdG)
measure the outcome with ELISA from blood sample in ng/mL numeric scale
Time frame: week 4
8-hydroxy-2-deoxyiguanosine (8-OHdG)
measure the outcome with ELISA from blood sample in ng/mL numeric scale
Time frame: week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.